The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder

The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder Publisher Pubmed

Shakeri J¹ ; Farnia V¹ ; Karimi AR¹ ; Tatari F¹ ; Juibari TA¹ ; Alikhani M¹ ; Bajoghli H² ; Holsboertrachsler E³ ; Brand S^{3, 4}

Show Affiliations

1. Substance Abuse Prevention Research Center, Psychiatry Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
2. Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran
3. Psychiatric Clinics of the University of Basel, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland
4. Department of Sport, Exercise and Health, Sport Science Section, Faculty of Medicine, University of Basel, Basel, Switzerland

Source: Drug and Alcohol Dependence Published:2016

Abstract

Background: Amphetamine abuse is increasing worldwide, and the occurrence of amphetamine-induced (AI) psychiatric issues further complicates treatment. In response, the DSM 5 has introduced the classification of amphetamine-induced obsessive-compulsive disorders (AI-OCD), though little has been published on either its prevalence rates or its clinical features. The aim of the present study was therefore to investigate the prevalence of AI-OCD, to describe patients' clinical features, and to compare the prevalence rate among such patients with those for OCD in the general population in Western countries and Iran. Methods: A total of 547 patients with amphetamine abuse or dependency and with a positive urine test (mean age: 31.64 years; 75.5% males) took part in the study. A psychiatric interview was carried out, covering both socio-demographic and illness-related information. Results: 18 (3.3%) patients suffered from OCD prior to amphetamine abuse, 491 (89.8%) had no OCD, and 38 (6.9%) suffered from AI. -OCD. Neither socio-demographic nor illness-related dimensions predicted patients with diagnosed AI-OCD. The prevalence of AI. -OCD was significantly higher than that for OCD in the general population (2.3% in Western countries, 1.8% in Iran). Conclusions: Data suggest that prevalence rate of AI. -OCD is about 7%. Neither socio-demographic nor illness-related dimensions predicted the occurrence of AI. -OCD. Thus, it remains unclear why some amphetamine abusers develop AI. -OCD while others do not. © 2016 Elsevier Ireland Ltd.

Related Docs

View other Related Docs

1. Demographic and Mental History-Related Data Predicted Occurrence of Psychosis in Metamphetamine Users, Psychiatry Research (2016)

2. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)

3. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)

4. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)

5. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)

6. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)

7. Repetitive Transcranial Magnetic Stimulation (Rtms) Improves Symptoms and Reduces Clinical Illness in Patients Suffering From Ocd - Results From a Single-Blind, Randomized Clinical Trial With Sham Cross-Over Condition, Journal of Psychiatric Research (2015)

8. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorder, But Also Cognitive Performance: Results From a Randomized Clinical Trial With a Cross-Over Design and Sham Condition, Neuropsychobiology (2016)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (5)

Farzin Rezaei (2)

Style	Citing Format
MLA	Shakeri J, et al.. "The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder." Drug and Alcohol Dependence, vol. 160, no. , 2016, pp. 157-162.
APA	Shakeri J, Farnia V, Karimi AR, Tatari F, Juibari TA, Alikhani M, Bajoghli H, Holsboertrachsler E, Brand S (2016). The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder. Drug and Alcohol Dependence, 160(), 157-162.
Chicago	Shakeri J, Farnia V, Karimi AR, Tatari F, Juibari TA, Alikhani M, Bajoghli H, Holsboertrachsler E, Brand S. "The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder." Drug and Alcohol Dependence 160, no. (2016): 157-162.
Harvard	Shakeri J et al. (2016) 'The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder', Drug and Alcohol Dependence, 160(), pp. 157-162.
Vancouver	Shakeri J, Farnia V, Karimi AR, Tatari F, Juibari TA, Alikhani M, et al.. The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder. Drug and Alcohol Dependence. 2016;160():157-162.
BibTex	@article{ author = {Shakeri J and Farnia V and Karimi AR and Tatari F and Juibari TA and Alikhani M and Bajoghli H and Holsboertrachsler E and Brand S}, title = {The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder}, journal = {Drug and Alcohol Dependence}, volume = {160}, number = {}, pages = {157-162}, year = {2016} }
RIS	TY - JOUR AU - Shakeri J AU - Farnia V AU - Karimi AR AU - Tatari F AU - Juibari TA AU - Alikhani M AU - Bajoghli H AU - Holsboertrachsler E AU - Brand S TI - The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder JO - Drug and Alcohol Dependence VL - 160 IS - SP - 157 EP - 162 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract